Kentucky Retirement Systems Insurance Trust Fund Has $1.22 Million Stock Position in Kenvue Inc. (NYSE:KVUE)

Kentucky Retirement Systems Insurance Trust Fund reduced its position in shares of Kenvue Inc. (NYSE:KVUE) by 7.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 56,877 shares of the company’s stock after selling 4,524 shares during the period. Kentucky Retirement Systems Insurance Trust Fund’s holdings in Kenvue were worth $1,221,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in KVUE. Mutual Advisors LLC grew its stake in shares of Kenvue by 6.1% during the fourth quarter. Mutual Advisors LLC now owns 10,606 shares of the company’s stock worth $228,000 after buying an additional 612 shares during the last quarter. CVA Family Office LLC bought a new stake in shares of Kenvue during the fourth quarter worth $32,000. Raymond James Financial Services Advisors Inc. grew its stake in shares of Kenvue by 3.7% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 604,176 shares of the company’s stock worth $13,008,000 after buying an additional 21,514 shares during the last quarter. Schechter Investment Advisors LLC grew its stake in shares of Kenvue by 54.6% during the fourth quarter. Schechter Investment Advisors LLC now owns 15,747 shares of the company’s stock worth $339,000 after buying an additional 5,564 shares during the last quarter. Finally, Planned Solutions Inc. bought a new stake in shares of Kenvue in the fourth quarter worth $27,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Price Performance

Shares of NYSE:KVUE traded up $0.13 during trading on Monday, reaching $18.82. The company had a trading volume of 3,442,484 shares, compared to its average volume of 18,932,586. The company has a fifty day moving average of $18.59 and a two-hundred day moving average of $19.53. The stock has a market capitalization of $36.04 billion, a P/E ratio of 23.96, a price-to-earnings-growth ratio of 2.07 and a beta of 1.41. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.43. The company has a current ratio of 0.99, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Tuesday, May 7th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.25 by $0.03. Kenvue had a net margin of 9.63% and a return on equity of 21.06%. The firm had revenue of $2.89 billion for the quarter, compared to analyst estimates of $3.79 billion. The company’s revenue was down 24.9% compared to the same quarter last year. Equities research analysts forecast that Kenvue Inc. will post 1.13 earnings per share for the current year.

Kenvue Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, August 28th. Shareholders of record on Wednesday, August 14th will be given a dividend of $0.205 per share. The ex-dividend date of this dividend is Wednesday, August 14th. This represents a $0.82 annualized dividend and a yield of 4.36%. This is a boost from Kenvue’s previous quarterly dividend of $0.20. Kenvue’s dividend payout ratio is presently 102.56%.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on KVUE shares. Sanford C. Bernstein began coverage on shares of Kenvue in a research note on Thursday, April 11th. They issued an “underperform” rating and a $18.00 price objective on the stock. HSBC upped their price objective on shares of Kenvue from $20.00 to $21.00 and gave the company a “hold” rating in a report on Wednesday, May 8th. JPMorgan Chase & Co. lowered their target price on shares of Kenvue from $23.00 to $22.00 and set an “overweight” rating on the stock in a report on Monday, July 22nd. Citigroup lowered their target price on shares of Kenvue from $21.00 to $20.00 and set a “neutral” rating on the stock in a report on Wednesday, July 10th. Finally, William Blair started coverage on shares of Kenvue in a research note on Wednesday, April 3rd. They issued a “market perform” rating for the company. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $22.45.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.